Search results
Results from the WOW.Com Content Network
Desmoid-type fibromatosis, also termed desmoid tumor and aggressive fibromatosis [26] Lipofibromatosis, a mixture of lipofibromatosis tumors with different gene abnormalities; [27] these tumors differ from lipofibromatosis-like neural tumors which have not been classified as fibroblastic and myofibroblastic tumors. Giant cell fibroblastoma [28]
Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm of the mesodermal cells that form the connective tissues which support virtually all of the organs and tissues of the body. [2] IMT was formerly termed inflammatory pseudotumor. [3]
Direct myofibroblastic differentiation of a progenitor cell resident in a stromal tissue. Homing and recruitment of a circulating mesenchymal precursor which can directly differentiate as above or indirectly differentiate through the other cell types as intermediates. Epithelial to mesenchymal transdifferentiation of an epithelial cell.
However its tumors have a distinctly different clinical presentation and histopathology than IMF. [24] The World Health Organization (2020) redefined infantile digital fibromatosis as a benign tumor in the category of benign fibroblastic and myofibroblastic tumors and therefore different than IMF. [25]
The World Health Organization in 2020 classified mammary type myofibroblastoma tumors and myofibroblastoma tumors (i.e. extramammary myofibroblastic tumors) as separate tumor forms within the category of fibroblastic and myofibroblastic tumors. [8] Mammary MFB likely represents less than 1% of all breast tumors. [9]
Acral myxoinflammatory fibroblastic sarcoma (AMSF), also termed myxoinflammatory fibroblastic sarcoma (MSF), is a rare, low-grade, soft tissue tumor that the World Health Organization (2020) classified as in the category of rarely metastasizing fibroblastic and myofibroblastic tumors. [1]
Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas. [1] As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of fibroblasts and smooth muscle cells) by Mentzel et al. in 1998. [2]
Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, [1] high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, [2] is characterized by the World Health Organization (WHO) as a rare, poorly differentiated neoplasm (i.e., an abnormal growth of cells that have an unclear identity and/or cell of origin). [3]